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INTRODUCTION
Independent genome-wide association studies (GWAS) have
identified multiple risk regions for many epithelial cancers in the
gene-poor region of chromosome 8q24 (Ghoussaini et al., 2008;
Haiman et al., 2007; Tomlinson et al., 2008; Zanke et al., 2007).
We (Jia et al., 2009; Pomerantz et al., 2009a) and others (Tuupanen
et al., 2009; Wasserman et al., 2010; Wright et al., 2010) have
identified enhancers in this region that loop to the potent oncogene
Myc, located 200-400 kb telomeric (Ahmadiyeh et al., 2010; Wright
et al., 2010), providing a plausible mechanism for risk. One of these
enhancers, originally identified by ChIP-chip analysis as a histone
H3 acetylation peak and designated AcP10 (Jia et al., 2009),
contains a risk single nucleotide polymorphism (SNP; rs6983267);
a G in this position is significantly associated with the pathogenesis
of prostate, colorectal and other cancers. The significance for
prostate cancer risk among Caucasians has one of the lowest
GWAS P-values (P6.210–23) (Al Olama et al., 2009). The risk-
associated SNP allele also facilitates increased binding of
transcription factor 7-like 2 (TCF7L2) (Pomerantz et al., 2009a;
Tuupanen et al., 2009) and confers on AcP10 higher enhancer
activity. Although AcP10 loops to Myc (Ahmadiyeh et al., 2010;
Wright et al., 2010), extensive expression quantitative trait locus
(eQTL) analyses in prostate and colorectal tumors and in normal
tissues have failed to demonstrate any association between risk
haplotypes and levels of Myc expression (Pomerantz et al., 2009a;
Pomerantz et al., 2009b; Tuupanen et al., 2009; Wright et al., 2010).
Apart from this intriguing but still unproven association with Myc
expression, the cellular and molecular mechanisms underlying the
increased prostate cancer risk mediated by AcP10 remain unclear.
Recently, Wasserman et al. carried out a bacterial artificial
chromosome (BAC) transgenic survey of the 8q24 region in which
they identified a 5 kb genomic fragment spanning rs6983267 that
was active in the mouse prostate (Wasserman et al., 2010). Stains
of whole prostates from postnatal day 21 (P21) mice suggested
overlap in Myc and transgene expression; however, no histological
analysis was performed, leaving identification of the cell type in
which the transgene was expressed unclear. Here we document a
link between AcP10 activity and a subpopulation of prostate cells
that is both a stem population and a potential cell of origin of
prostate cancer.
The prostate contains three epithelial cell types: lumenal
secretory cells, basal cells and neuroendocrine cells (Marker et al.,
2003). Prostate stem cells have been initially identified within the
basal cell population (Goldstein et al., 2010b), but androgen
depletion and replenishment experiments have demonstrated the
presence of stem cells within the lumenal compartment (Wang et
al., 2009). The growth and maintenance of the prostate are strongly
dependent on androgens (Marker et al., 2003). When androgens
are depleted by castration, the prostate undergoes involution.
During this process, most lumenal cells, and a smaller percentage
of basal cells, are lost. Shen and colleagues (Wang et al., 2009) have
identified a population of lumenal epithelial cells that persists after
androgen ablation. These cells are characterized by their expression
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SUMMARY
Regions in the 8q24 gene desert contribute significantly to the risk of prostate cancer and other adult cancers. This region contains several DNA
regions with enhancer activity in cultured cells. One such segment, histone acetylation peak 10 (AcP10), contains a risk single nucleotide polymorphism
(SNP) that is significantly associated with the pathogenesis of colorectal, prostate and other cancers. The mechanism by which AcP10 influences
cancer risk remains unknown. Here we show that AcP10 contains a sequence that is highly conserved across terrestrial vertebrates and is capable
in transgenic mice of directing reporter gene expression to a subset of prostate lumenal epithelial cells. These cells include a small population of
Nkx3.1-positive cells that persist even after androgen ablation. Castration-resistant Nkx3.1-positive (CARN) cells were shown by others to function
both as stem cells and cells of origin of prostate cancer. Our results thus provide a mechanism by which AcP10 could influence prostate cancer risk.
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of the homeobox gene Nkx3.1, whose expression is regulated by
androgens and in turn regulates the development of the prostate
epithelium. A functional variant in NKX3.1 is also associated with
prostate cancer susceptibility and downregulates its expression
(Akamatsu et al., 2010). In normal adult mice, Nkx3.1 is expressed
in most or all lumenal cells. Despite its expression-dependence on
androgens, a small population of Nkx3.1-positive cells remains after
androgen depletion. These cells, designated castration-resistant
Nkx3.1-positive (CARN) cells, are capable of giving rise to all three
prostate epithelial lineages (Wang et al., 2009). Moreover, these cells
can serve as a cell of origin in PTEN-mediated prostate cancer
development in mice (Wang et al., 2009).
In the present study, we used a transgenic approach to assess the
cell-type specificity of AcP10 activity. We show that a 1.5 kb
fragment, spanning the rs6983267 ancestral and risk G allele, contains
a DNA sequence with exceptionally highly conservation in mammals,
birds and reptiles. We further show that, in mice, this sequence directs
reporter gene expression to a small subset of epithelial cells of the
prostate, colon, breast and skin, but not to cells of the lung or liver.
Androgen ablation experiments suggest, strikingly, that AcP10 is
active in CARN cells. It is also active in a subset of Myc-expressing
cells. Our results provide a plausible mechanism as to how AcP10
can influence cancer risk: by affecting the Myc pathway in a set of
cells crucial for prostate growth and tumorigenesis.
RESULTS
The AcP10 enhancer region is highly conserved among
vertebrates
To identify conserved and thus potentially functional DNA
elements in the AcP10 region, we compared syntenic DNA
Fig. 1. Conservation of the AcP10 enhancer in terrestrial vertebrates and geographical distribution of the rs6983267 SNP. (A)We used software available
on the University of California Santa Cruz (UCSC) genome browser to assess the degree of DNA sequence conservation in the region of the AcP10 enhancer.
Shown is the Placental Mammal Basewise Conservation assessed by PhyloP (blue vertical lines), and vertebrate Multiz alignment of sequences from rhesus
monkey, mouse, dog, elephant, opossum, platypus, chicken, lizard, Xenopus tropicalis and stickelback (black vertical lines). The 1.5 kb fragment containing the
AcP10 enhancer is indicated by the horizontal line above. The nucleotide sequence of the region surrounding the rs6983267 functional SNP is shown below.
Note that all species shown have the G allele. (B)Global distribution of the high-risk G allele and lower risk T allele of rs6983267 as assessed by the UCSC genome
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segments across diverse vertebrate groups (Fig. 1). We identified
a sequence of 1750 nucleotides that was highly conserved among
placental and marsupial mammals. This sequence contained a core
of 450 nucleotides that was significantly conserved in mammals,
reptiles and birds. The functional SNP, rs6983267, shown previously
to be causally associated with risk of prostate cancer (Haiman et
al., 2007), lay just outside this core sequence, within the region
exhibiting conservation among mammals (Fig. 1A). Interestingly,
the ancestral G allele imposes prostate cancer risk in multiple
populations and might be related to the known higher risk of
prostate cancer among recent descendants of Africans such as
African-Americans (Fig. 1B).
A conserved AcP10 sequence is sufficient to direct lacZ reporter
expression to prostate, mammary gland, colon and hair follicle
To investigate the mechanism by which AcP10 might influence
cancer risk, we asked whether a fragment bearing the conserved
region is capable of driving reporter gene expression to specific
Fig. 2. AcP10 directs reporter gene
expression to cells of the prostate,
mammary gland, colon and skin.
We produced transgenic mouse lines
carrying the AcP10-hsp68-lacZ
construct. We examined three such
lines for transgene expression in
mouse tissues (A-H). Tissues were
sectioned and stained for -gal
activity (blue) and counterstained
with nuclear fast red. (A)Sections of
prostate from a control, non-
transgenic mouse. (B)Sections of
prostate from lines 1, 2 and 3. Note
-gal-positive cells in lumenal
epithelium in each line. Line 2 was
further examined for  galactosidase
expression in the colon (C),
mammary gland (D), skin (E), liver (F),
lung (G) and spleen (H). Note
expression in colon, mammary gland
and skin. AP, anterior prostate; DLP,
dorsolateral prostate; VP, ventral
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tissues in transgenic mice. We produced a transgene in which the
1.5 kb fragment was inserted in a vector containing the hsp68
minimal promoter and lacZ [encoding -galactosidase (-gal)]
reporter gene. This vector has been used extensively for assessing
enhancer activity in vivo (Brugger et al., 2004).
We injected the construct into mouse zygotes and produced
three independent transgenic lines. We examined 8-week-old
animals of each line for -gal expression in a variety of tissues.
Representative examples are shown in Fig. 2. Staining was apparent
in prostate, colon, mammary gland and hair follicle. No staining
was detected in liver or lung. The tissue distribution of -gal activity
was similar in the three independent transgenic lines (Fig. 2 and
data not shown), suggesting that position effects were not the cause
of tissue-specific transgene expression.
The AcP10 transgene is expressed in lumenal epithelial cells of the
prostate
We examined -gal expression in greater detail in the prostates of
line 2. The mouse prostate has three lobes: anterior, dorsolateral
and posterior. As is evident in Fig. 3, -gal-positive cells were
present in all three lobes, but were more abundant in the anterior
lobe. Images of sections at higher magnification showed that -
gal-positive cells were located largely, if not exclusively, in the
lumenal epithelium (Fig. 3). Co-staining of sections with an
antibody against CK8, a marker for lumenal epithelial cells (Xue
et al., 1998), and an antibody against -gal, showed that all -gal-
positive cells are also positive for CK8 (Fig. 4). Staining with an
antibody against CK5, which marks basal cells (Xue et al., 1998),
showed no overlap with -gal. These results show that the -gal-
positive cells are lumenal epithelial cells.
The AcP10 transgene is expressed in a subset of cells resistant to
androgen ablation and positive for Nkx3.1
Although there is considerable evidence that basal cells contain a
stem population (Goldstein et al., 2010a), recent work shows that
the lumenal compartment also contains stem cells (Wang et al.,
2009). These cells are marked by continued expression of Nkx3.1
after androgen ablation. We asked whether AcP10–-gal-positive
cells also expressed Nkx3.1. We co-stained sections of prostates of
AcP10–-gal transgenic mice with antibodies against -gal and
Nkx3.1. The distribution of AcP10-positive cells in the different
lobes of the prostate was unchanged following androgen ablation
(data not shown). As reported previously, Nkx3.1 was expressed
in all or most lumenal epithelial cells (Wang et al., 2009) (Fig. 5).
Following castration, Nkx3.1-positive cells were reduced to small
patches of cells and individual cells, consistent with the findings of
Wang et al. (Wang et al., 2009). A comparison of the Nkx3.1
expression pattern with that of AcP10–-gal showed that the two
signals overlapped partially (Fig. 5F,I). The fact that the overlap was
not greater suggested that there was not a simple gene regulatory
relationship between AcP10 and Nkx3.1 in which, for example, one
is necessary and sufficient for the expression of the other. It
remained possible, however, that there was a non-random
association between the two. To test this possibility, we counted
foci positive for AcP10-driven -gal and Nkx3.1 individually, and
foci positive for both. We used a chi-square (2) test to investigate
whether the number of foci positive for both was greater than
expected from chance alone. As is evident from data presented in
Table 1, counts performed on four mice consistently showed an
association significantly greater than expected, and yielded an
overall P<0.001 that the association was due to chance (Mantel-
Fig. 3. Expression of AcP10-hsp68-lacZ
transgenic line 2 in different regions of
the prostate. Positive cells were present in
the anterior prostate (AP; A,D,G), the
dorsolateral prostate (DLP; B,E,H) and the
ventral prostate (VP; C,F,I). Higher
magnification images show that virtually all
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Haenszel test). These data suggest that AcP10 and Nkx3.1 are
associated in a regulatory network. The less than perfect correlation
between Nkx3.1 and AcP10 expression suggests that this
association is complicated by input from additional factors in a
complex regulatory network.
AcP10 is active in prostate tumors in mice that have targeted
inactivation of Pten in the prostate
We next investigated whether AcP10 is active in prostate tumors.
We made use of the Pten model of prostate cancer in which the
Pten tumor suppressor gene is inactivated in the prostate by means
of Cre-mediated recombination driven by the prostate-specific
probasin-Cre (Wang et al., 2003). Previous work established that
probasin-Cre mediates efficient recombination of the floxed Pten
allele (Wang et al., 2003). In this system, virtually 100% of
homozygous mutant mice develop tumors within 9 weeks (Wang
et al., 2003). We produced mice homozygous for the floxed Pten
allele and also carrying probasin-Cre. We examined prostates of
Pten-probasin-Cre conditional mutants aged 7-9 months. As
expected, all mutants examined had prostate tumors (n7). As
previously described (Wang et al., 2003), prostates in mutant mice
contained regions of normal morphology, as well as areas of
prostatic intraepithelial neoplasia (PIN) and frank adenocarcinoma.
Counting of -gal-positive clusters revealed no significant
concentration in any of these three tissue types (data not shown).
Marker analysis with the basal marker CK5 and the lumenal marker
CK8 showed that AcP10-positive tumor cells, like their normal
counterparts, co-express CK8 (Fig. 6); thus loss of Pten function
did not influence the cell type in which AcP10 was expressed.
DISCUSSION
Here we address the mechanism by which highly conserved, non-
coding DNA elements within the 8q24 gene desert influence
cancer risk. Previously we identified a subregion of 8q24, AcP10,
that contains a risk SNP and has enhancer activity in cultured cells
(Jia et al., 2009). In the present study, we show that a 1.5 kb
fragment, including a highly conserved DNA sequence in which
the SNP is embedded, directs reporter gene expression to a subset
of lumenal epithelial cells in the prostate. These include some cells
that persist after androgen ablation and express the transcription
factor Nkx3.1. Shen and colleagues demonstrated that these cells,
designated castration-resistant Nkx3.1-positive (CARN) cells, are
both stem cells and potential cells of origin of prostate cancer (Wang
et al., 2009). We show, moreover, that AcP10 is active in cells of
prostate tumors developing in mice in which the Pten gene is
inactivated in the prostate. Our results thus provide a plausible
mechanism by which the AcP10 enhancer element can influence
prostate cancer risk.
Accumulating evidence shows that highly conserved, non-coding
elements (CNEs) can have gene regulatory functions (Bulger and
Groudine, 2011). The human genome contains many thousands of
such elements, which are likely to have originated as retroposons
and in some instances have acquired a function in the host genome,
a process known as exaptation (Santangelo et al., 2007). Some CNEs
have been shown to function as tissue-specific enhancers. In most
but not all cases they are also defined by their extremely high degree
of DNA sequence conservation across vertebrates (Birney et al.,
2007). At least some CNEs are under negative selection, implying
that the extremely high degree of sequence conservation is required
for function.
The AcP10 element has a central region approximately 450 bp
in length that is conserved across terrestrial vertebrates, exhibiting
approximately 67% identity to a sequence in lizards. This high
degree of conservation suggests a fundamental and slowly evolving
function in vertebrates. Such a function might include controlling
gene expression in the prostate or in tissues from which the prostate
evolved, such as the Mullerian duct (Wake, 1981).
We note that the AcP10 element drives expression in epithelial
tissues of the breast, colon and skin, but not in epithelia generally.
We have not yet identified the specific cell types in these tissues
in which the AcP10 transgene is expressed. This is likely to be of
interest at least in the colon because AcP10 is associated with risk
of colon cancer as well as prostate cancer.
The fact that the high-risk (G) allele of the SNP rs6983267 is the
ancestral allele is evident in comparisons across vertebrates showing
the G allele in all groups. It is also apparent in the geographic
distribution of the two alleles in humans, which shows the high
risk G allele in African populations and the low-risk T allele outside
Africa, consistent with the T allele emerging as ancestral humans
migrated out of Africa. The T allele might have conferred a
selective advantage, perhaps reducing the risk of cancer.
Grandparent effects (Hawkes, 2010) on allele frequency – i.e.
selection acting at the level of extended family or group – could
explain fixation of an allele that does not provide a direct advantage
to individuals of reproductive age.
Fig. 4. AcP10 is active in prostate lumenal epithelial cells. Immunostaining
with the basal cell marker CK5 (A,E; green fluorescence) and the lumenal cell
marker CK8 (B,F; green fluorescence) showed that -gal (C-F; red fluorescence)
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An approach that has been used by several groups to identify
stem cells in the mouse prostate is to reduce androgen levels by
physical or chemical castration and examine the cells remaining
after this treatment (Wang et al., 2009). When androgens are
withdrawn, the prostate involutes to a small size. Resupplying
androgens causes the gland to regenerate. All the cells required to
regenerate the gland are most likely present in the involuted gland
following androgen ablation. Using this approach, Shen and
colleagues (Wang et al., 2009) showed that a subset of lumenal
epithelial cells remain in androgen-depleted prostates. These
CARN cells are capable of giving rise to an entire prostate, and are
also a cell of origin of prostate cancer.
As we noted previously (Jia et al., 2009), AcP10 has chromatin
marks consistent with enhancer activity. Moreover, it can function
as an enhancer in cultured cells. Thus, we expected AcP10 to drive
reporter gene expression in transgenic mice. We were surprised,
however, at the remarkable specificity of transgene expression in
a subset of prostate epithelial cells. Marker analysis showed that
the AcP10–-gal-positive cells are lumenal. Positive cells tend to
be clustered, implying that such cells are clonally related.
Until recently, only basal epithelial cells were thought to contain
stem populations and to serve as cells of origin of prostate cancer
(Goldstein et al., 2010a). New findings by the Shen group (Wang
et al., 2009) that the lumenal compartment might also have stem
cells prompted us to investigate whether the AcP10–-gal-positive
cells exhibit molecular characteristics of lumenal epithelial stem
cells. Shen and colleagues showed that the transcription factor
Nkx3.1 is expressed in all or most lumenal epithelial cells in control
mice (Wang et al., 2009). Upon androgen depletion by castration,
the prostate is greatly reduced in size, and Nkx3.1 expression is
Fig. 5. AcP10 is active in a subset of CARN cells. AcP10-hsp68-lacZ line 2 mice were castrated at 2 months after birth. After 2 weeks, prostates were sectioned
and the sections co-stained with antibodies against Nkx3.1 (A,D,G) and -gal (B,E,H). Nkx3.1 (green) was expressed in most or all lumenal epithelial cells of the
normal prostate (A). -gal activity (red) was apparent in a subset of these cells (B). In post-castration prostates (D-I), both Nkx3.1 and -gal were expressed in a
small subset of cells compared with the normal prostate (compare D-I with A-C). Moreover, in a significant number of cells, Nkx3.1 and -gal expression
overlapped (F,I). 






AcP10– -gal-positive foci also
expressing Nkx3.1 (%)
AcP10– -gal-negative foci that
express Nkx3.1 (%) P-value
1 6699 1.8 9.1 3.0 <0.001
2 7134 1.5 9.2 5.8 0.14
3 7297 2.2 8.8 4.0 0.003
4 3102 1.4 6.7 1.6 0.008
Overall/Average – 1.7 8.5 3.6 <0.001
We counted foci expressing -gal and Nkx3.1 and estimated the total number of foci (Nkx3.1-expressing foci + AcP10-expressing foci + non-expressing foci) as described in the
Methods. The percent of cells/foci expressing Nkx3.1 was compared between foci that were positive vs negative for -gal. The chi-square test (based on the 2 2 table) was used to
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retained in a small subset of lumenal cells. Our results show that
about 8.5% of AcP10-positive cells are also positive for Nkx3.1,
compared with 3.6% of AcP10-negative cells (Table 1). Chi-square
analysis suggests that this overlap in expression patterns is
significant (P<0.001).
That AcP10 is not expressed in all Nkx3.1-positive cells suggests
that there is not a simple relationship between the enhancer
activity of AcP10 and the identity of such cells or the regulation of
Nkx3.1. Thus it is not likely that the main function of AcP10 is to
regulate the expression of Nkx3.1 in lumenal epithelial cells; nor
is it probable that Nkx3.1 is a main determinant of the activity of
AcP10 in such cells. Rather, the increased likelihood that AcP10 is
expressed in Nkx3.1-positive cells suggests that AcP10 and Nkx3.1
are linked in a regulatory network, although perhaps distantly. Even
a distant link, however, could be part of the explanation of how
AcP10 increases the risk of prostate cancer. Shen and colleagues
(Wang et al., 2009) showed that Nkx3.1-positive cells are also
potential cells of origin of prostate cancer in a Pten mouse model.
Thus, our results connect the AcP10 enhancer to a population of
cells that can self renew, produce prostate epithelial cell types after
injection into the mouse kidney capsule, and give rise to prostate
tumors (Wang et al., 2009).
Our overall hypothesis is that AcP10 controls the expression of
a gene(s) whose activity is crucial for tumorigenesis. One possible
AcP10-regulated gene is Myc. We showed previously that AcP10
loops to Myc, and that the risk allele of rs6983267 enhances TCF7L2
binding to the enhancer (Pomerantz et al., 2009a). This result led
us to predict that Myc expression in prostate tumors would
correlate with the SNP genotype. We found that this was not the
case, however. There was no eQTL relationship between SNP
genotype and Myc expression in tumors. It remains possible that
AcP10 modulates Myc expression levels transiently in a tumor
precursor cell, an idea also suggested by Wasserman and colleagues
(Wasserman et al., 2010). We carried out immunostaining with an
anti-Myc antibody and found that Myc protein was expressed
widely in the prostate epithelium (data not shown), consistent with
the findings of Wasserman and colleagues (Wasserman et al., 2010).
Although there was some overlap with AcP10 expression, the broad
distribution of Myc made it impossible to determine whether this
overlap occurred by chance. Clearly, because AcP10 is expressed
in few Myc-positive cells, it is not likely to be a principal
determinant of Myc expression in the prostate. Nevertheless,
AcP10 might have a quantitative effect on Myc expression in a
subset of cells. Such an effect could be sufficient to predispose such
cells to oncogenic transformation and thus explain the elevated risk
of prostate cancer associated with the rs6983267 genotype.
Highly conserved, non-coding elements such as AcP10 are thought
to be derived from retroposons (Bejerano et al., 2006). Although the
function of such elements is unclear, at least some undergo
exaptation, a process by which they are co-opted as participants in
a cellular regulatory process that is beneficial to the host organism
(Bejerano et al., 2006). Such a process might include the acquisition
of an ability to regulate gene expression in a tissue-specific manner
and thus control cellular identity. AcP10 could be such an element,
and AcP10-expressing cells could have a distinct identity and set of
properties, perhaps related to prostate function or development. A
key unanswered question is whether the association of AcP10 with
oncogenesis is related to such a function in normal prostate
development, or is a consequence of a fortuitous ability of AcP10 to
direct gene expression to the prostate lumenal epithelium.
METHODS
Generation of DNA constructs for microinjection
An AcP10 (chr8:128482318-128483856; 1538 bp) fragment was
released from the AcP10/tk-luc plasmid (Jia et al., 2009) by SacII
restriction endonuclease digestion, blunt-filled with Quick Blunting
Kit, followed by subcloning into the SmaI site of pKSBlue-hsp-lacZ
vector. Sequencing revealed the proper insertion in the forward
direction of the pKSBlue-hsp-lacZ vector.
Production and genotyping of transgenic mice
AcP10-pKSBlue-hsp-lacZ transgenic mouse embryos and lines
were generated in the Norris Cancer Center Transgenic/Knockout
Mouse Core by pronuclear injection as described by Liu et al. (Liu
et al., 1994). DNA was prepared from mouse tails or embryo yolk
sacs and used for genotyping of the lacZ allele by PCR as described
(Kwang et al., 2002).
Pten prostate cancer model
cPten–/–; AcP10-pKSBlue-hsp-lacZ mice were generated by
crossing of the prostate-specific Pten homozygous-deletion mice
with AcP10-pKSBlue-hsp-lacZ transgenic mice. The parental male
Fig. 6. AcP10 is active in prostate tumors. We produced mice with the
genotype AcP10-lacZ; Ptencko/cko; probasin-Cre. We examined the prostates of
these mice after 5 months when virtually 100% had prostate tumors. We
carried out immunostaining for the basal cell marker CK5 (A), the lumenal cell
marker CK8 (B) and -gal (C,D). Overlapped images are shown in E and F. Note
clusters of -gal-positive cells in areas of the prostate that have a tumor
phenotype (C,D). Note also that the -gal signal is found exclusively in cells
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mouse harboring the probasin-Cre (PB-Cre4) transgene and floxed
Pten (f Pten) allele was described previously (Wang et al., 2003).
Histology and immunostaining
Mouse prostates were embedded in OCT medium (Histoprep;
Fisher Scientific) before sectioning. Analysis of -gal activity on
frozen sections was carried out as described (Ishii et al., 2003).
Immunofluorescence was performed using chicken anti-E. coli -
gal (ab9361; Abcam), rabbit anti-mouse CK5 (AF 138; Covance),
rat anti-mouse CK8 (TROMA-1 antibody; Developmental Studies
Hybridoma Bank, University of Iowa), and rabbit anti-mouse
Nkx3.1 (a kind gift from Cory Abate-Shen, Columbia University,
NY) diluted in goat serum at 4°C overnight. Detection of primary
antibody of -gal, CK5 and CK8 was performed by incubating
rhodamine/FITC-labeled goat anti-chicken/rabbit/rat IgY/G (1:100)
for 1 hour at room temperature followed by DAPI counterstaining.
Detection of Nkx3.1 signal using TSA Plus Fluorescence Systems
(PerkinElmer) was carried out as described (Wang et al., 2009).
Statistics
We counted the number of foci that expressed AcP10–-gal and/or
Nkx3.1. Foci contained an average of 15 cells. The total number of
‘foci’, including expressing and non-expressing cells, was determined
by counting the total cell number in a given area and extrapolating
to the entire slide. Total cell number was divided by the average
size of a focus to give the total number of foci. At least 20 sections
were counted for each slide, which was derived from one mouse.
A total of four mice were counted. The percent of cells/foci
expressing Nkx3.1 was compared between foci, which were positive
vs negative for AcP10–-gal. The Pearson chi-square test (based
on the 22 table) was used to measure the strength of this
difference within each slide. To obtain an ‘overall’ P-value across
the four mice, the Mantel-Haenszel chi-square test was used.
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TRANSLATIONAL IMPACT
Clinical issue
The genetic risk factors for prostate cancer remain poorly characterized. 8q24
is a genomic region that has recently been found to have a highly significant
association with prostate cancer risk. 8q24 is a gene desert, and the molecular
mechanisms by which it might increase cancer risk are unclear. Previous work
by this group showed that a risk-associated single nucleotide polymorphism
(SNP) within 8q24 (rs6983267) lies within a genomic region with chromatin
marks that are associated with active enhancers. This region, designated
AcP10, was found to have enhancer activity in cultured cells. 
Results
Now, the authors report on the function of AcP10 in vivo to further elucidate
how this region confers prostate cancer risk. They show that a 1.5 kb fragment
spanning the risk-associated SNP drives reporter gene expression in a subset
of lumenal epithelial cells in the mouse prostate. These cells have
characteristics of a recently identified population of stem cells, in that they
remain after castration and express the marker gene Nkx3.1. Other work has
shown that castration-resistant Nkx3.1-expressing cells have stem-like
properties and are a cell of origin for prostate tumors in a Pten knockout
mouse model. 
Implications and future directions
This work documents that AcP10 is an enhancer that can drive reporter
expression in a population of putative stem cells in the prostate. Identifying
the genes and processes regulated by AcP10 might help to explain how
prostate tumors develop, as well as aid in the development of interventions
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